Search results for "ANTIGENS"

showing 10 items of 1928 documents

Dermal CD207-Negative Migratory Dendritic Cells Are Fully Competent to Prime Protective, Skin Homing Cytotoxic T-Lymphocyte Responses

2018

Dendritic cells (DCs) are important inducers and regulators of T-cell responses. They are able to activate and modulate the differentiation of CD4+ and CD8+ T cells. In the skin, there are at least five phenotypically distinct DC subpopulations that can be distinguished by differential expression of the cell surface markers CD207, CD103, and CD11b. Previous studies have suggested that dermal CD11b−CD207+ conventional type 1 DCs are indispensable for the priming of a skin homing cytotoxic T-lymphocyte response. However, conventional type 1 DCs are also the only skin DC subset capable of cross-presenting exogenous antigens on major histocompatibility complex class I. Thus, it remained unclear…

0301 basic medicineLangerhans cellEpitopes T-LymphocytePriming (immunology)Mice TransgenicVaccinia virusDermatologyCD8-Positive T-LymphocytesBiologyMajor histocompatibility complexBiochemistryMice03 medical and health sciencesCross-Priming0302 clinical medicineAntigenmedicineAnimalsHumansCytotoxic T cellMolecular BiologySkinintegumentary systemCluster of differentiationHistocompatibility Antigens Class ICell BiologyDendritic cellCell biologyDisease Models Animal030104 developmental biologymedicine.anatomical_structureLangerhans Cells030220 oncology & carcinogenesisSkin Diseases Viralbiology.proteinImmunologic MemoryCD8T-Lymphocytes CytotoxicJournal of Investigative Dermatology
researchProduct

Selective AhR knockout in langerin-expressing cells abates Langerhans cells and polarizes Th2/Tr1 in epicutaneous protein sensitization

2020

The aryl hydrocarbon receptor (AhR) represents an environmental sensor regulating immune responses. In the skin, AhR is expressed in several cell types, including keratinocytes, epidermal Langerhans cells (LC), and dermal dendritic cells (DC). The mechanisms how AhR activates or inhibits cutaneous immune responses remain controversial, owing to differences in the cell-specific functions of AhR and the different activating ligands. Therefore, we sought to investigate the role of AhR in LC and langerin(+) and negative DC in the skin. To this aim, we generated Langerin-specific and CD11c-specific knockout ((−/−)) mice lacking AhR, respectively, in LC and Langerin(+) dermal DC and in all CD11c(…

0301 basic medicineLangerinOvalbuminMice TransgenicAdministration CutaneousImmunoglobulin ET-Lymphocytes RegulatoryGene Knockout TechniquesMice03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemBasic Helix-Loop-Helix Transcription FactorsmedicineAnimalsLectins C-TypeInterleukin 5SensitizationMultidisciplinaryintegumentary systembiologyChemistryImmunoglobulin EBiological Sciencesrespiratory systemAryl hydrocarbon receptorMolecular biologyOvalbuminMannose-Binding Lectins030104 developmental biologymedicine.anatomical_structureReceptors Aryl HydrocarbonLangerhans CellsAntigens SurfaceInterleukin 13biology.proteinEpidermis030215 immunologyProceedings of the National Academy of Sciences
researchProduct

The New Structure of Core Oligosaccharide Presented by Proteus penneri 40A and 41 Lipopolysaccharides

2018

The new type of core oligosaccharide in Proteus penneri 40A and 41 lipopolysaccharides has been investigated by 1H and 13C NMR spectroscopy, electrospray ionization mass spectrometry and chemical methods. Core oligosaccharides of both strains were chosen for structural analysis based on the reactivity of LPSs with serum against P. penneri 40A core oligosaccharide–diphtheria toxoid conjugate. Structural analyses revealed that P. penneri 40A and 41 LPSs possess an identical core oligosaccharide.

0301 basic medicineLipopolysaccharidesSpectrometry Mass Electrospray IonizationMagnetic Resonance SpectroscopyStereochemistryElectrospray ionizationOligosaccharidesanti-conjugate serum; core oligosaccharide; lipopolysaccharide; NMR spectroscopy; ESI MS; <i>Proteus penneri</i>Immune seraProteus penneriCatalysisArticleInorganic Chemistrycore oligosaccharidelcsh:Chemistry03 medical and health sciencesStructure-Activity Relationship13c nmr spectroscopyNMR spectroscopyMoleculePhysical and Theoretical ChemistryESI MSMolecular Biologylcsh:QH301-705.5SpectroscopyAntigens Bacterial030102 biochemistry & molecular biologybiologyMolecular StructureChemistryCore oligosaccharideImmune Seraanti-conjugate serumOrganic ChemistrylipopolysaccharideGeneral MedicineNuclear magnetic resonance spectroscopybiology.organism_classificationProteus penneriComputer Science Applicationslcsh:Biology (General)lcsh:QD1-999ConjugateInternational Journal of Molecular Sciences
researchProduct

New insights into the genetic component of non-infectious uveitis through an Immunochip strategy.

2016

BACKGROUND: Large-scale genetic studies have reported several loci associated with specific disorders involving uveitis. Our aim was to identify genetic risk factors that might predispose to uveitis per se, independent of the clinical diagnosis, by performing a dense genotyping of immune-related loci.METHODS: 613 cases and 3693 unaffected controls from three European case/control sets were genotyped using the Immunochip array. Only patients with non-infectious non-anterior uveitis and without systemic features were selected. To perform a more comprehensive analysis of the human leucocyte antigen (HLA) region, SNPs, classical alleles and polymorphic amino acid variants were obtained via impu…

0301 basic medicineMale*meta-analysisSingle-nucleotide polymorphismHuman leukocyte antigenBiology*human leukocyte antigenPolymorphism Single NucleotideWhite PeopleUveitis03 medical and health sciences0302 clinical medicine*Immunochiphuman leukocyte antigenHLA AntigensRisk FactorsGeneticsmedicineJournal ArticleHumansGenotypingGenetics (clinical)Allelesnon-anterior uveitisGeneticsHaplotypenon-infectious uveitisImmunochipMiddle Agedmedicine.diseaseBirdshot chorioretinopathymeta-analysis030104 developmental biologyHaplotypesGenetic Loci*non-anterior uveitisCase-Control StudiesImmunology*non-infectious uveitis030221 ophthalmology & optometryIntermediate uveitisFemaleGene polymorphismUveitis
researchProduct

Aging-associated genes and let-7 microRNAs: a contribution to myogenic program dysregulation in oculopharyngeal muscular dystrophy

2019

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscle disease caused by an abnormal (GCN) triplet expansion within the polyadenylate-binding protein nuclear 1 gene and consequent mRNA pr...

0301 basic medicineMaleAgingOculopharyngealMuscle DevelopmentBiochemistryMyoblasts0302 clinical medicine80 and overMuscular DystrophyHMGB1 ProteinPAX7 Transcription FactorCell DifferentiationdifferentiationMiddle AgedCell biologymedicine.anatomical_structureFemaleMyogeninMitogen-Activated Protein KinasesBiotechnologyDifferentiation regeneration skeletal muscleAdultBiologyInclusion BodyOculopharyngeal muscular dystrophy03 medical and health sciencesmicroRNAGeneticsmedicineHumansGenetic Predisposition to Diseasedifferentiation; regeneration; skeletal muscle; Adult; Aged; Aged 80 and over; Aging; Antigens Neoplasm; Cell Differentiation; Female; Gene Expression Regulation; HMGB1 Protein; Humans; Male; MicroRNAs; Middle Aged; Mitogen-Activated Protein Kinases; Muscle Development; Muscular Dystrophy Oculopharyngeal; Myoblasts; Myogenin; Myositis Inclusion Body; PAX7 Transcription Factor; Genetic Predisposition to Diseaseskeletal muscleAntigensMolecular BiologyGeneAgedMessenger RNAMyositisRegeneration (biology)Skeletal musclemedicine.diseaseMicroRNAs030104 developmental biologyMuscle diseaseGene Expression RegulationregenerationNeoplasm030217 neurology & neurosurgery
researchProduct

Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients

2019

The lysosome has a key role in the presentation of lipid antigens by CD1 molecules. While defects in lipid antigen presentation and in invariant Natural Killer T (iNKT) cell response were detected in several mouse models of lysosomal storage diseases (LSD), the impact of lysosomal engorgement in human lipid antigen presentation is poorly characterized. Here, we analyzed the capacity of monocyte-derived dendritic cells (Mo-DCs) from Fabry, Gaucher, Niemann Pick type C and Mucopolysaccharidosis type VI disease patients to present exogenous antigens to lipid-specific T cells. The CD1b- and CD1d-restricted presentation of lipid antigens by Mo-DCs revealed an ability of LSD patients to induce CD…

0301 basic medicineMaleAntigens CD1d / metabolismMucopolysaccharidosis type VIMonocytes / metabolismLysosomal Storage Diseases / diagnosisAntigens CD10302 clinical medicineAntigens CD1 / metabolismLysosomal storage diseaseImmunology and AllergyChildOriginal ResearchAged 80 and overAntigen PresentationbiologyKiller Cells Natural / metabolism*lipid antigen presentationAntigen Presentation / immunologyMiddle AgedNatural killer T cellLipidsnatural killer T cellsKiller Cells Naturalmedicine.anatomical_structureCD1DDendritic Cells / metabolismChild Preschool*dendritic cellsFemalelipids (amino acids peptides and proteins)*natural killer T cellsDisease SusceptibilitymonocytesAdultlcsh:Immunologic diseases. AllergyAdolescentT cellImmunologyCD1chemical and pharmacologic phenomenaCD1bLysosomal Storage Diseases / metabolismCD1dImmunophenotyping03 medical and health sciencesYoung AdultAntigenLysosomemedicineDendritic Cells / immunologyHumans*monocytesLymphocyte Countdendritic cellslysosomal storage diseasesLysosomal Storage Diseases / etiologyKiller Cells Natural / immunologyAgedbusiness.industry*CD1dInfantlipid antigen presentationmedicine.diseaseMonocytes / immunology*CD1b*lysosomal storage diseases030104 developmental biologyImmunologybiology.proteinAntigens CD1dbusinesslcsh:RC581-607Lipids / immunologyBiomarkers030215 immunology
researchProduct

Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pulmonary non tuberculosis disease.

2018

We used the Luminex Bead Array Multiplex Immunoassay to measure cytokines, chemokines and growth factors responses to the same antigens used for RD1-based Interferon γ Release Assay (IGRA) test. Seventy-nine individuals, 27 active TB, 32 latent infection subsets, 20 individuals derivative purified protein (PPD) negative (subjects that do not have any indurative cutaneous reaction after 72 hrs of intradermal injection of PPD) and with other pulmonary disease were retrospectively studied. Forty-eight analytes were evaluated by Luminex Assay in plasma obtained from whole blood stimulated cells. The diagnostic accuracies of the markers detected were evaluated by ROC curve analysis and by the co…

0301 basic medicineMaleBacterial DiseasesPhysiologylcsh:MedicineBiochemistry0302 clinical medicineBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Immune PhysiologyBlood plasmaMedicine and Health SciencesMultiplex030212 general & internal medicinelcsh:ScienceWhole bloodInnate Immune SystemMultidisciplinarymedicine.diagnostic_testLatent tuberculosisbiologyChemotaxis3. Good healthBody FluidsActinobacteriaCell MotilityInfectious DiseasesBloodCytokinesTuberculosis Diagnosis and ManagementChemokinesAnatomyResearch ArticleAdultTuberculosisSettore MED/17 - Malattie InfettiveImmunologyBlood PlasmaMycobacterium tuberculosis03 medical and health sciencesAntigenLatent TuberculosisDiagnostic MedicinemedicineSettore MED/05 - Patologia ClinicaHumansTuberculosisTuberculosis PulmonaryAntigens BacterialBiochemistry Genetics and Molecular Biology (all)Bacteriabusiness.industrylcsh:ROrganismsBiology and Life SciencesMycobacterium tuberculosisCell BiologyMolecular Developmentmedicine.diseasebiology.organism_classificationTropical Diseases030104 developmental biologyAgricultural and Biological Sciences (all)ImmunoassayImmune SystemImmunologylcsh:QbusinessBiomarkersDevelopmental BiologyPloS one
researchProduct

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

2015

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d with weekly dose increases; n = 23) or flat (112 μg/d; n = 2) dosing of blinatumomab by continuous infusion, with dexamethasone prophylaxis, in patients with relapsed/refractory DLBCL. Patients received a median of 3 prior lines of therapy. Median time since last regimen was 1.5 months. Seventeen patients ended treatment in cycle 1 (induction), 7 in cycle 2 (consolidation), and 1 in retreatment. Am…

0301 basic medicineMaleCD3 ComplexClinical Trials and ObservationsSalvage therapyPhases of clinical researchKaplan-Meier EstimateBiochemistryGastroenterologyDexamethasone0302 clinical medicineRecurrenceAntibodies BispecificMedicineMolecular Targeted TherapyFatigueRemission InductionHematologyMiddle AgedTumor Burden030220 oncology & carcinogenesisBlinatumomabFemaleImmunotherapyLymphoma Large B-Cell Diffusemedicine.drugAdultmedicine.medical_specialtyFeverImmunologyAntigens CD19Antineoplastic AgentsDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesAntigens NeoplasmInternal medicineHumansDosingAdverse effectAgedSalvage TherapyDose-Response Relationship Drugbusiness.industryCell Biologymedicine.diseaseLymphomaSurgeryRegimen030104 developmental biologyNervous System DiseasesbusinessDiffuse large B-cell lymphomaBlood
researchProduct

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

2017

Supplemental Digital Content is available in the text.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT-LymphocytesEpitopes T-LymphocyteT-Cell Antigen Receptor SpecificityImmunotherapy AdoptiveEpitopeCohort StudiesExon0302 clinical medicineimmune system diseasesImmunology and AllergyMedicineProtein IsoformsChildAged 80 and overbiologyCD19CART-19B-ALLMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomaepitope-lossmedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisChild PreschoolComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleClone (B-cell biology)Gene isoformAdultAdolescentRecombinant Fusion ProteinsImmunologyAntigens CD19Receptors Antigen T-CellCancer VaccinesCD1903 medical and health sciencesYoung AdultAntigenHumansAgedPharmacologybusiness.industryInfant NewbornisoformsInfantImmunotherapy030104 developmental biologyImmunologybiology.proteinClinical StudyTumor EscapeBone marrowbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.

2017

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Its clinical course is typically indolent; however, based on a series of pathobiological, clinical, genetic, and phenotypic parameters, patient survival varies from less than 5 to more than 20 years. In this paper, we show for the first time that the expression of the interferon-inducible DNA sensor IFI16, a member of the PYHIN protein family involved in proliferation inhibition and apoptosis regulation, is associated with the clinical outcome in CLL. We studied 99 CLLs cases by immunohistochemistry and 10 CLLs cases by gene expression profiling. We found quite variable degrees of IFI16 expression among CLLs cases. No…

0301 basic medicineMaleChronic lymphocytic leukemiaGene Expressionhemic and lymphatic diseasesGene expression80 and overImmunology and AllergyChronicNuclear ProteinCD20Aged 80 and overLeukemiaMembrane GlycoproteinsZAP-70 Protein-Tyrosine KinasebiologyZAP70Nuclear ProteinsGeneral MedicineMiddle AgedPhenotypeImmunohistochemistryLymphocyticchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; Adult; Aged; Aged 80 and over; Antigens CD38; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Leukemia Lymphocytic Chronic B-Cell; Male; Membrane Glycoproteins; Middle Aged; Nuclear Proteins; Phosphoproteins; Treatment Outcome; Young Adult; ZAP-70 Protein-Tyrosine Kinase; Gene Expression; Immunology and Allergy; 2734; Microbiology (medical)LeukemiaTreatment OutcomePhosphoproteinimmunohistochemistryImmunohistochemistryZAP70FemaleMembrane GlycoproteinprognosiHumanMicrobiology (medical)Adult2734IFI16; ZAP70; chronic lymphocytic leukemia; gene expression; immunohistochemistry; prognosisNOPathology and Forensic Medicine03 medical and health sciencesYoung AdultmedicineHumansAntigensIFI16Agedbusiness.industryGene Expression ProfilingB-Cellchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; ADP-ribosyl Cyclase 1; Adult; Aged; Aged 80 and over; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Leukemia Lymphocytic Chronic B-Cell; Male; Membrane Glycoproteins; Middle Aged; Nuclear Proteins; Phosphoproteins; Treatment Outcome; Young Adult; ZAP-70 Protein-Tyrosine Kinase; Gene Expression; 2734; Immunology and Allergy; Microbiology (medical)medicine.diseasePhosphoproteinsADP-ribosyl Cyclase 1Leukemia Lymphocytic Chronic B-CellGene expression profilingchronic lymphocytic leukemia; gene expression; IFI16; immunohistochemistry; prognosis; ZAP70; Immunology and Allergy; 2734; Microbiology (medical)030104 developmental biologygene expressionCancer researchbiology.proteinchronic lymphocytic leukemiaprognosisbusinessCD38APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
researchProduct